Colgate-Palmolive (NYSE: CL) reported mixed first-quarter results and lowered its full-year guidance amid concerns over rising U.S. tariffs and a weakening consumer environment.
Earnings per share came in at $0.85, slightly below the Street expectations of $0.87. Revenue reached $4.91 billion, just ahead of the consensus forecast of $4.89 billion.
Despite the modest revenue beat, the consumer goods manufacturer adjusted its outlook downward, now anticipating organic sales growth of 2% to 4% for the year, compared to its prior range of 3% to 5%. The revision reflects anticipated headwinds from new trade policies and a more cautious consumer base.
Data shows that inflation expectations are climbing while consumer sentiment continues to soften—factors that could lead to more price-sensitive behavior and slower demand for branded household products.
Colgate-Palmolive also narrowed its earnings growth forecast, now targeting low-single-digit EPS growth, versus an earlier estimate of low to mid-single digits. Gross margin is expected to remain roughly flat as a percentage of net sales, versus the previous outlook calling for stability or slight improvement.
While global market uncertainty persists, the company emphasized its commitment to execution and cost discipline to navigate the current environment and meet its revised 2025 financial targets.
As of the latest update, Colgate-Palmolive (NYSE: CL) stock is up 0.73%, trading at $94.60.
David Kirakosyan is a seasoned financial journalist with nearly a decade of hands-on experience in covering the U.S. stock markets. Since 2016, he has written thousands of equity news articles, detailed market analyses, and investment insights for trusted platforms like Benzinga, Investing.com, and StreetInsider. David holds a Master of Science in Finance and is a Level 2 CFA® candidate, reflecting his deep commitment to financial expertise and ethical standards. His reporting combines real-world market experience with a strong academic foundation, helping readers make informed decisions backed by reliable information. Read Full Bio
